Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:
“Single arm phase II study of irinotecan + anlotinib for platinum-resistant SCLC published Lung Cancer Journal (n=37). RR 62%, PFS 4.5m, OS 7.2m.
Tarlatamab is the standard here but still need novel agents. Always hard to interpret single arm SCLC studies.”
Title: Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study
Journal: Lung Cancer Journal
Article: Minna Zhang, Yi Tang, Jiafeng Liang, Lucheng Zhu, Bing Wang, Kaicheng Pan, Xiao Xu, Xueqin Chen, Bing Xia
More posts featuring Stephen V Liu on OncoDaily.